

This is the sole purpose for which the company will be authorized by the DEA to import morphine.

**Louis J. Milione,**

*Assistant Administrator.*

[FR Doc. 2017-04647 Filed 3-8-17; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-392]

#### Bulk Manufacturer of Controlled Substances Application: Mallinckrodt, LLC

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before May 8, 2017.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with

respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on November 14, 2016, Mallinckrodt, LLC, 3600 North Second Street, Saint Louis, Missouri 63147 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Gamma Hydroxybutyric Acid .....	2010	I
Tetrahydrocannabinols .....	7370	I
Codeine-N-oxide .....	9053	I
Dihydromorphine .....	9145	I
Difenoxin .....	9168	I
Morphine-N-oxide .....	9307	I
Normorphine .....	9313	I
Norlevorphanol .....	9634	I
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) .....	9821	I
Butyl Fentanyl .....	9822	I
Amphetamine .....	1100	II
Methamphetamine .....	1105	II
Lisdexamfetamine .....	1205	II
Methylphenidate .....	1724	II
Nabilone .....	7379	II
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....	8333	II
Codeine .....	9050	II
Dihydrocodeine .....	9120	II
Oxycodone .....	9143	II
Hydromorphone .....	9150	II
Diphenoxylate .....	9170	II
Ecgonine .....	9180	II
Hydrocodone .....	9193	II
Levorphanol .....	9220	II
Meperidine .....	9230	II
Methadone .....	9250	II
Methadone intermediate .....	9254	II
Dextropropoxyphene, bulk (non-dosage forms) .....	9273	II
Morphine .....	9300	II
Oripavine .....	9330	II
Thebaine .....	9333	II
Opium tincture .....	9630	II
Opium, powdered .....	9639	II
Oxymorphone .....	9652	II
Noroxymorphone .....	9668	II
Alfentanil .....	9737	II
Remifentanil .....	9739	II
Sufentanil .....	9740	II
Tapentadol .....	9780	II
Fentanyl .....	9801	II

The company plans to manufacture bulk active pharmaceutical ingredients (APIs) for distribution to its customers.

**Louis J. Milione,**

*Assistant Administrator.*

[FR Doc. 2017-04645 Filed 3-8-17; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

[Docket No. DEA-392]

#### Importer of Controlled Substances Application: Meda Pharmaceuticals, Inc.

**AGENCY:** Drug Enforcement  
Administration, Justice.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic class, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.34(a) on or before April 10, 2017. Such persons may also file a written request for a hearing on the application pursuant to 21 CFR 1301.43 on or before April 10, 2017.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All request for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/LJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant

Administrator") pursuant to section 7 of 28 CFR part 0, appendix of subpart R.

In accordance with 21 CFR 1301.34(a), this is notice that on December 5, 2016, Meda Pharmaceuticals, Inc., 705 Eldorado Street, Decatur, Illinois 62523 applied to be registered as an importer of nabilone (7379), a basic class of controlled substance listed in schedule II.

The company plans to import the FDA approved drug product in finished dosage form for distribution to its customers. Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2).

**Louis J. Milione,**

*Assistant Administrator.*

[FR Doc. 2017-04648 Filed 3-8-17; 8:45 am]

**BILLING CODE 4410-09-P**

## DEPARTMENT OF JUSTICE

### Foreign Claims Settlement Commission

[F.C.S.C. Meeting and Hearing Notice No.  
3-17]

#### Sunshine Act Meeting

The Foreign Claims Settlement Commission, pursuant to its regulations (45 CFR 503.25) and the Government in the Sunshine Act (5 U.S.C. 552b), hereby gives notice in regard to the scheduling of open meetings as follows:

*Thursday, March 23, 2017: 10:00 a.m.*—Issuance of Proposed Decisions in claims against Iraq.

*Status:* Open.

All meetings are held at the Foreign Claims Settlement Commission, 600 E Street NW., Washington, DC. Requests for information, or advance notices of intention to observe an open meeting, may be directed to: Patricia M. Hall, Foreign Claims Settlement Commission, 600 E Street NW., Suite 6002, Washington, DC 20579. Telephone: (202) 616-6975.

**Brian M. Simkin,**

*Chief Counsel.*

[FR Doc. 2017-04739 Filed 3-7-17; 11:15 am]

**BILLING CODE 4410-BA-P**

## DEPARTMENT OF JUSTICE

[Docket No. ODAG 170]

### Notice of Federal Advisory Committee Meeting

**AGENCY:** Department of Justice.

**ACTION:** Notice of Federal Advisory Committee meeting. Request for public comment.

**SUMMARY:** The National Commission on Forensic Science will hold meeting thirteen at the time and location listed below.

**DATES:** *Public Hearing.* The meeting will be held on April 10, 2017 from 9:00 a.m. to 5:00 p.m. and April 11, 2017 from 9:00 a.m. to 4:30 p.m.

*Written Public Comment.* Written public comment regarding National Commission on Forensic Science meeting materials can be submitted through [www.regulations.gov](http://www.regulations.gov) starting on March 27, 2017. Any comments should be posted to [www.regulations.gov](http://www.regulations.gov) no later than 11:59 p.m. (EST) April 12, 2017.

**ADDRESSES:** Office of Justice Programs, 3rd Floor Main Conference Room, 810 7th Street NW., Washington, DC 20531.

**FOR FURTHER INFORMATION CONTACT:** Jonathan McGrath, Ph.D., Senior Policy Analyst at the National Institute of Justice and NCFS Designated Federal Officer, 810 7th Street NW., Washington, DC 20531, by email at [Jonathan.McGrath@usdoj.gov](mailto:Jonathan.McGrath@usdoj.gov) or by phone at (202) 514-6277.

#### SUPPLEMENTARY INFORMATION:

*Agenda:* The Commission will receive subcommittee status updates and briefings. A final agenda will be posted to the Commission's Web site in advance of the meeting.

*Meeting Accessibility:* Pursuant to 41 CFR 102-3.140 through 102-3.165 and the availability of space, the meeting scheduled for April 10, 2017, 9:00 a.m. to 5:00 p.m. and April 11, 2017, 9:00 a.m. to 4:30 p.m. at the Office of Justice Programs is open to the public and webcast. Seating is limited and pre-registration is strongly encouraged. Media representatives are also encouraged to register in advance.

*Written Comments:* Pursuant to section 10(a)(3) of the FACA and 41 CFR 102-3.105(j) and 102-3.140, the public or interested organizations may submit written comments to the Commission in response to the stated agenda and meeting material. Meeting material, including work products, will be made available on the Commission's Web site: <http://www.justice.gov/ncfs>.

*Oral Comments:* In addition to written statements, members of the public may present oral comments at 4:45 p.m. on April 10, 2017 and at 3:15 p.m. on April 11, 2017. Those individuals interested in making oral comments should indicate their intent through the on-line registration form and time will be allocated on a first-come, first-served